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Abstract 
Background 
Though patient needs are key drivers of treatment decisions, they are rarely 
systematically investigated in routine care.  
Objective 
This study aimed at analysing needs and expectations from the patient perspective in 
the German and Swiss psoriasis registries PsoBest and SDNTT with respect to 
treatment choice, age and gender.  
Methods 
The German and Swiss psoriasis registries observe patients recruited at first-time 
use of systemic drugs. Within 10 years, clinical (Psoriasis Area Severity Index 
(PASI), Body Surface Area (BSA)) and patient-reported outcomes are documented, 
including the Dermatology Quality of Life Index (DLQI) and the Patient Benefit Index 
(PBI), characterizing patient needs for treatment. The analysis dataset includes 
n=4,894 patients from PsoBest and n=449 from SDNTT with mean follow-up time of 
7.5 months. 
Results 
5,343 patients registered between 2008 and 2016 were included in the analyses (at 
baseline: 59.6 % male, mean age 47.6 years±14.5, PASI 14.2±9.7, BSA 22.7±19.7, 
DLQI 11.3±7.2).The most important patient needs were to “get better skin quickly” 
and to “be healed of all skin defects”. 
Subgroup analyses by age revealed significant differences in needs, especially 
higher needs regarding social impairments in patients younger than 65 years. 
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Patients 65 years or older attributed more importance to sleep quality, less 
dependency on medical visits, fewer side effects and confidence in the therapy. Out 
of 25 items reflecting patient needs, 20 items were rated significantly more important 
by women than men, with the greatest differences regarding feeling of depression, 
sleep quality and everyday productivity. Divided by treatment, needs were rated 
differently, recommending individualized and targeted choice of therapy. 
Conclusion 
Age and gender stratify patient needs. Women showed higher expectations and 
rated specific needs in psoriasis treatment higher than men. Analyzing the patient 
needs on an individual level will facilitate shared decisions by patient and physician in 
finding the optimal personalized treatment. 
Keywords: patient needs, psoriasis, quality of life  
 
Introduction 
 
2.5 % of the German and Swiss population are affected by psoriasis1. This chronic 
disease can severely impact patient's quality of life2, which can be improved greatly 
by new treatments. 
Dermatologists’ primary goal in treatment of psoriasis is objective improvement of 
extent of involvement. However, priorities differ between patients and physicians3. 
Psoriasis patients rate itching as much more bothersome than extent of involvement3. 
Patients’ views and quality of life have increasing importance in the decision between 
different systemic treatment options. Hence, patient burden and needs are not 
sufficiently anticipated by the clinician4. This could be a reason why some patients 
with psoriasis feel misunderstood and not sufficiently perceived by their doctor as 
outlined in the Global Psoriasis Report (WHO 2016). This report concludes that a 
“patient-centered care” is needed, which implies shared decisions and substantial 
patient empowerment. The report also recommends to measure patient needs in a 
proper way and highlights the broad spectrum of patient needs in psoriasis care5,6.  
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The patient needs questionnaire (PNQ), which records the needs far beyond quality 
of life instruments like the Dermatology Life Quality Index (DLQI)7-9 and which 
determines these needs in five dimensions, was used in this analyses.  
Beside data on needs already published6, only limited data is available about a big 
cohort and patient needs respective age, gender or treatment choice. The current 
study investigated this topic in to our knowledge largest prospective psoriasis cohorts 
in two European countries.  
 
Methods 
Patient population and data collection 
Adult patients with moderate to severe psoriasis who started systemic anti-psoriatic 
treatment were prospectively included in the national psoriasis registries of Germany 
(PsoBest) and Switzerland (Swiss Dermatology Network of Targeted Therapies 
(SDNTT)). In Germany, data was collected in 820 office-based dermatology practices 
and hospital-based outpatient clinics, in Switzerland by eight academic dermatology 
departments. The patients of the registry correspond to those in routine care and 
reflect real-life data10. The observation period runs up to 10 years. The patients have 
not previously been treated with inclusion treatment. 
The two registries are registered with ClinicalTrials.gov (PsoBest: NCT01848028, 
SDNTT: NCT01706692). Before the start of the registries, ethical approval, if 
required for participating centers, was obtained. The registries suggest psoriasis 
treatment according to the European consensus paper on treatment goals in 
psoriasis11 and the S3 guidelines for the treatment of psoriasis12.  
This analysis focused on the baseline data of all patients included between October 
21, 2011 (SDNTT) or December 17, 2007 (PsoBest) until 31 December 2016, all 
having received one of the following therapies at the time of their inclusion: 
methotrexate, fumaric acid esters, ciclosporine, acitretin, apremilast, adalimumab, 
etanercept, infliximab, ustekinumab, secukinumab. The data acquisition was done 
according to the harmonized PsoNet study protocol, the international standards of 
epidemiological studies, requests of pharmacovigilance, and the German AWMF 
guidelines concerning the collection of life-quality data in dermatology12. CVderm 
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data management independently monitored and approved the data of all patient 
visits.  
For analyses, patients were assigned to treatment groups based on therapy at 
inclusion. 
 
Statistical analysis  
Descriptive analyses were performed using standard parameters (absolute/ relative 
frequencies, means, SD). For comparisons, U-test, Chi-squared-test or Analysis of 
Variances (ANOVA) were used. Patients’ needs were differentiated according to the 
specific treatment, patient age (< 65 years vs.  ≥65 at baseline) and gender. 
 
Assessments 
Treatment needs and benefits were evaluated by using the PBI13 subscales of the 
first part of the PBI, the Patient Needs Questionnaire (PNQ) at baseline (Table 1). 
Values between 0 (not important at all) and 4 (very important) are possible. Five PBI 
subscales are distinguished: 1 = reducing psychological impairments; 2 = reducing 
social impairments; 3 = reducing impairments due to therapy, 4 = reducing physical 
impairments; 5 = building confidence into therapy8. 
 
Results 
Patients 
Overall, 5,343 patients were included in the analysis (4,894 PsoBest and 449 SDNTT 
patients).  
The majority of patients were male (59.6 %), the mean age was 47.6 years (Table 2). 
Patients had a mean weight of 85.5 kg (mean BMI 28.4) and 42.3 % were currently 
smoking (17.3 pack years on average). 37.6 % of the patients indicated that a first-
degree relative was affected by psoriasis. The mean PASI was 14.2, the mean Body 
Surface Area (BSA) 22.7. Approximately every other patient had nail psoriasis (51.4 
%, 6.6 nails involved on average), 19.1 % of patients had psoriatic arthritis. 
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Comparison of registries regarding baseline parameters revealed Swiss patients to 
be slightly younger (46.2 vs. 47.7 years, p ≤ 0.037), lighter (83.4 vs. 85.7 kg, p ≤ 
0.021), and more predominantly male (65.9 % vs. 59.0 %, p ≤ 0.004). As compared 
to PsoBest, SDNTT patients showed significantly lower disease severity (mean PASI 
9.9 vs 14.6, mean BSA 14.0 vs. 23.5, both p ≤ 0.001), but more SDNTT patients 
suffered from nail psoriasis (60.8 % vs. 50.6 %, p ≤ 0.001) than PsoBest participants. 
 
Patient needs 
The most important reported patient needs were to “get better skin quickly” (94.0 % 
"quite/very important", mean PNQ score 3.7 +/- 0.7) and “be healed of all skin 
defects” 94.0 % "quite/very important", mean PNQ score 3.7 +/- 0.8) (Fig. 1). 92 % of 
all patients considered the parameters “to have confidence in the therapy” as well as 
“regain control of the disease” as important (both 92.0 % "quite/very important", mean 
PNQ score 3.6 +/- 0.9). Of lesser importance were social goals including “to be less 
burdened in your partnership” (57.7%, 2.3 +/- 1.7), “to be less of a burden to relatives 
and friends” (54.6 %, 2.3 +/- 1.7), “to be able to have a normal sex life” (54.0 %, 2.2 
+/- 1.8) and “to be able to have more contact with other people” (52.0 %, 2.2 +/- 1.7). 
The least important item to our patients was “be able to lead a normal working life” 
(49.7 %, 2.0 +/- 1.8). 
 
The seven need items rated highest by over 80 % of patients did not differ between 
treatment cohorts. However, other needs, i.e. those reported to be important by less 
than 70 % of patients, varied between treatment cohorts (Fig. 2). Especially the 
concern about side effects was reported at therapy start most frequently for 
apremilast (77.3 % "quite/very important") and ustekinumab (75.9 % "quite/very 
important"). In contrast, patients who started a treatment with fumaric acid esters 
indicated less fear about side effects to be one of their individual patient needs (61.0 
% "quite/very important", Fig. 2). The registers did not indicate different profiles in 
patient needs between Germany and Switzerland. 
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Differences in treatment aims by age 
Out of 25 PNQ items, 13 items were differentially rated in importance depending on 
age (Fig. 3). The younger patients (< 65 years of age at treatment start) rated the 
following aims at a higher level: “to no longer have burning sensations on your skin” 
(mean PNQ score 2.9 vs. 2.6, p ≤ 0.002), “to feel less depressed” (2.4 vs. 2.2, p ≤ 
0.029), “to be able to lead a normal working life” (2.2 vs. 0.5, p ≤ 0.001), “to be 
comfortable showing yourself more in public” (3.1 vs. 2.6, p ≤ 0.001), “to be less 
burdened in your partnership” (2.4 vs. 2.0, p ≤ 0.001), “to be able to have a normal 
sex life” (2.3 vs. 1.6, p ≤ 0.001). Higher needs in older patients (≥65 years of age at 
treatment start) were found for: “to be able to sleep better” (2.2 vs. 2.1, p ≤ 0.024), “to 
be less dependent on doctor and clinic visits” (3.2 vs. 3.1, p ≤ 0.001), “to have fewer 
side effects” (2.9 vs. 2.8, p≤ 0.031) and “to have confidence in the therapy” (3.7 vs. 
3.6, p ≤ 0.001) highest. 
 
Gender differences in treatment aims  
Gender medicine has highlighted certain differences in diseases and treatment 
outcomes between women and men. We therefore evaluated differences in patient 
needs related to gender. Here, differences were even more distinct than those 
regarding patient age.  
Out of the 25 items, there was a significant difference in 20 of them, all rated more 
important by women than men. Only, the aims: “to be less of a burden to relatives 
and friends”, “to be able to lead a normal working life”, “to be able to have more 
contact with other people”, “to be less burdened in your partnership”, and to “to be 
able to have a normal sex life” were not rated with significant differences between 
men and women (Fig. 4). 
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Discussion 
 
Even though studies focusing on psoriasis treatment are abundant, they rarely 
investigate specific patient needs. Our study addressed this gap by systematically 
characterizing patient reported needs with respect to treatment based on prospective 
data collected in the German and Swiss psoriasis registries.  
The dimensions of patient needs which were assessed independently from the 
treatment decision were shown to cover a wide range including social, physical, 
psychosocial burden, the desire to have confidence in therapy and impairment due to 
treatment (Table 1). The present data provide insights into individualized treatment 
goals and decisions. Differences found may come not unexpected to experienced 
clinical dermatologists. Our results indicate that women tend to suffer more intensely 
from this disease or at least stated higher treatment needs than men. This might 
possibly be driven by distinct aesthetic and social norms that women experience in 
our society14,15. We here have to point out, that the patient needs were assessed at 
treatment start and therefore are no result of treatment chosen but patient’s 
expectation to treatment. 
The complete dataset was stratified for gender and age to allow a more in-depth 
analysis of these subgroups.  
 
Gender differences in treatment goals of psoriasis patients  
Female psoriasis patients indicated to have overall higher expectations of therapy. 
Whether this is due to a higher subjective priority of women’s appearance and ability 
to perform in daily life remains unclear. The items of the PNQ subscale social 
impairment were rated equally in 5 of 6 items by men and women, except of “be 
comfortable showing yourself more in public”, which was more important to women. 
This indicates that appearance itself is more important to women. On the other hand, 
not only in this study both men and women stated great importance to the needs 
statement on social relationships, partnership and sex16. This indicates that the 
impact of the skin condition on relationships should be further explored. 
Psychological factors playing a role during exacerbation of psoriasis flares should be 
taken into diagnostic consideration17. Psoriasis patients report onset of lesions to be 
triggered by stress in more than 50%. Negative disease coping and suppression of 
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stress burdens influence psoriasis to an extend that flares occur more rapidly and 
severely. Finally, the association with alcohol and possible suicidal tendencies has 
been shown in several studies, especially for men1,18.  
Our results suggest that especially for female patients, strategies for individualized 
shared decisions are required to manage expectations correctly and to cope with 
disease burden. To our knowledge, this is the first analysis in a registry study 
comprising two countries that focus on this topic, which in the time of personalized 
medicine is rapidly gaining importance. Blome et al. did not find differences regarding 
age or gender when analysing treatment needs and their consistency over time6. 
However, there are some interesting gender differences regarding frequency of 
hospitalization19. There are higher hospitalization rates in men than in women.  
Age differences in treatment goals  
The sub-analysis of patient needs depending on age showed quite a few differences: 
For younger patients “having a normal work life” and “having a normal sex life” was 
significantly more important. This difference, as could have been expected, confirms 
that elderly patients have distinct needs from their younger counterparts.  
In contrast, older patients attributed more importance than younger participants to 
specific needs like “to be able to sleep better”, “to be less dependent on doctor and 
clinic visits”, “to have fewer side effects” and “to have confidence in the therapy”. One 
reason for this might be that elderly patients more often have sleeping disorders and 
in general see their physician more often. Furthermore, being older, the psoriasis is 
expected to last longer and therefore overall more treatments have been 
unsatisfactory as confidence in therapy gains weight. 
So far, the subject of patients’ needs in psoriasis and their correlation with age has 
not been investigated sufficiently6,20,21. However, age-associated skin conditions and 
diseases were identified by the International League of Dermatological Societies, 
who found that the consequences of skin aging is one of the most important grand 
challenges in global skin health.  Overall it is known that healthy skin during life 
course leads to better mental and emotional health, positive impact on social 
engagement, and healthier, more active, and productive lives22.  
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Treatment goals 
Overall, itching (or rather, the absence of it) was found to be a frequent treatment 
goal, which is in line with publications indicating the high prevalence of itch in 
psoriasis23,24.  
Moreover, “getting a better skin quickly”, “be healed of all skin defects”, “be able to 
lead a normal daily life”, “be comfortable showing yourself more in public” are all 
related to having less disease visibility. In daily consultations, patients regularly 
express those needs25,26. 
According to our analysis, “to have confidence in therapy” was more important than 
“having fewer side effects”. This could suggest that people who are confident of a 
specific treatment and well informed about possible side effects tolerate those better. 
Each patient has his individual profile of expectations and needs with regard to the 
desired treatment outcome and acceptable side effects (“have fewer side effects”). 
This profile is registered during the consultation and implicitly used to choose the 
best therapeutic option. In addition, the psychological precondition and impairment of 
quality of life of the patient might contribute to these needs. Formalised and validated 
methods are available for its characterization. The oldest as well as the simplest of 
these tools is the DLQI. However, it has the disadvantage of lacking robust scales for 
the dimensions of quality of life as well as the characteristics of the DLQI score as a 
sum score counting “did not apply to me” as score 07,8,27. Newer tools, like the Patient 
Needs Questionnaire used in this study, are able to differentiate the patients’ needs 
into 5 different dimensions, namely reducing psychological impairments, reducing 
social impairments, reducing impairments due to therapy, reducing physical 
impairments and building confidence into therapy8. They focus on needs rather on 
burden and thus facilitate communication related to treatment goals. We believe that 
the Patient Needs Questionnaire is hereby very helpful and more accurate than the 
DLQI when defining patients’ needs. Accurate information concerning patients’ needs 
can be helpful in selecting specific drugs that best fit the profile of the respective 
patient, thus resulting in a more personalized treatment approach.  
„To be free of pain“ was of greater importance in patients with psoriatic arthritis (PsA) 
and are in line with higher rated needs like “to get better skin quickly”, “be healed of 
all skin defects”, “to have confidence in the therapy”, “regain control of the disease”, 
“find a clear diagnosis and therapy”, “be free of itching”, “have no fear that the 
disease will become worse” among patients using drugs effective against arthritis. By 
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contrast, patients on fumaric acid esters, which are not effective in PsA, showed a 
very low needs score for pain reduction. Even though MTX is a first-line treatment in 
psoriasis arthritis, the need score for pain reduction is rated less in MTX-treated 
patients compared to the biologicals. 
There were clear differences between groups regarding treatment choice in terms of 
needs for reduced side effects and tolerability. In particular, the association between 
lower patient need for side effects and fumaric acid ester treatment was striking in 
the light of subjective side effects and public safety discussions28,29, it is not 
surprising that patients who started with fumaric acid ester treatment, rate the need 
for safe treatment at a lower level. However, the PBI was not explicitly used for such 
a selection. For this, the finding of specific patient needs profiles by drug rather 
reflect the results of obviously careful physician-patient interaction and patient-
centred care. By contrast, patients starting a biological treatment all showed high 
expectations regarding the absence of side effects, which matches with the lower 
rate of intolerance and side effects associated with these drugs.  
Analyzing patient needs with regard to disease course (“have no fear that the 
disease will progress”), we found that patients starting with apremilast rated the 
importance of this need lower than those receiving other drugs. We surmise that 
patients having a high level of fear of progression will be less willing to start a 
treatment with a considerable risk of failure such as apremilast, which is known to 
have a good tolerability and safety profile, but low efficacy30. 
We suggest that for treatment decisions, individual patient needs should be 
examined to identify and appropriately address patient-derived concerns. Some 
needs statements showed more distinct answer patterns than others, leading to a 
higher variance. 
A better understanding of patient needs could help physicians achieve better therapy 
outcomes, higher patient satisfaction and quality of care31,32. Consequently, 
surrogate markers that reproducibly quantify patients’ needs are gaining value. The 
more efficiently psoriasis patients’ needs are addressed, the better the therapy 
adherence and ultimately the disease control.  During the consultation, physicians 
need to assess the best individual treatment option based on the individual patient 
needs. We believe that the PBI questionnaire could be a helpful tool in this context.  
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In the future, the assessment of patient needs will allow to set specific individual 
treatment goals as well as projection and overall implementation of the patient benefit 
index. The questionnaire used in both registries allows patient-relevant needs and 
therapy benefit7.  
Taken together, analyzing the patient needs on an individual level will facilitate 
shared decisions by patient and physician in finding the optimal personalized 
treatment.  
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Tables 
Table 1 Patient needs questionnaire and its subscales 
  
Reducing social impairments 
• To be less of a burden to relatives and friends 
• To be able to lead a normal working life 
• To be able to have more contact with other people 
• To dare to show oneself more 
• To be less burdened in partnership 
• To be able to have a normal sex life 
Reducing psychological impairments  
• To feel less depressed 
• To gain in joy of living 
• To be able to lead a normal everyday life 
• To be more capable in daily life 
• To be able to engage in normal leisure activities 
Reducing impairments due to therapy 
• To be less dependent on doctor and clinic visits 
• To have to spend less time with daily care 
• To have fewer out-of-pocket treatment costs 
• To experience fewer side-effects 
Reducing physical impairments 
• To be free of pain 
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• To be free of itching 
• To no longer have a burning sensation on the skin 
• To be healed of all skin alterations 
• To be able to sleep better 
Having confidence in healing 
• To have no fear that the disease will progress 
• To find a clear diagnosis and therapy 
• To have confidence in the therapy 
Not attributed to subscales 
• To regain control of the disease 
• To get better skin quickly 
 
Table 2 Patient characteristics  
  N Minimum Maximum Mean / % SD 
Age [y] 5345 18.0 92.0 47.6 14.5
Weight [kg] 5296 38.0 200.0 85.5 19.5
BMI [kg/m²] 5288 14.7 63.3 28.4 5.9
Gender (Female) 5346 . . 40.4 .
PASI 5237 0.0 66.6 14.2 9.7
BSA 5238 0.0 100.0 22.7 19.7
DLQI 5070 0.0 30.0 11.3 7.2
Nail Psoriasis 5346 . . 51.4 .
Psoriatic Arthritis 5346 . . 19.1 .
*Missing data were not inputed, but total of available data is shown as collected 
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Figure Legends 
 
Figure 1 Goals to reach for psoriasis patients sorted by overall importance and sub 
grouped by inclusion treatment (n = 5,343). 
(ADA, adalimumab; ALL, overall treatments APR, apremilast; ETA, etanercept; FAE, 
fumaric acid esters; SEC, secukinumab; UST, ustekinumab; MTX, methotrexate) 
 
Figure 2 Mean deviation from overall importance of treatment goals in psoriasis 
patients by inclusion treatment (n = 5,343). 
(ADA, adalimumab; APR, apremilast; ETA, etanercept; FAE, fumaric acid esters; 
SEC, secukinumab; UST, ustekinumab; MTX, methotrexate) 
 
Figure 3 Difference in patients need by age group (n = 5,343). 
(* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001) 
 
Figure 4 Differences in patient needs by gender (n = 5,343). 
(* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001)  
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
